



Independent Auditors' Report

To the Members of
CHANDAN PHARMACY LIMITED
Report on the Audit of the Financial Statements

Opinion

We have audited the Financial Statements of **CHANDAN PHARMACY LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st March, 2022, and the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our ethical responsibilities in



accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Director's Report, Report on Corporate Governance and General Shareholders Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast



significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.


- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure 'A' statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Companies Act, 2013, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d. In our opinion, the aforesaid financial statements comply with the Accounting Standards prescribed under Section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014.



- e. On the basis of the written representations received from the directors as on 31st March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2022 from being appointed as a director in terms of Section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure 'B' ; and
- g. with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which were required to be transferred, to the Investor Education and Protection Fund by the Company.

For GAGAN JAIN & ASSOCIATES
Chartered Accountants

UDIN- 22529925BDQEXP2868

FCA Gagan Jain
Proprietor
Membership No.529925

Place:- MEERUT
Date:- 23.09.2022




ANNEXURE-"A" TO THE INDEPENDENT AUDITOR'S REPORT


Referred to in Paragraph 1 under the heading of "report on other legal and regulatory requirements" of our report of even date

As required by the Companies (Auditor's Report) Order, 2020 issued by the Government of India in terms of section 143(11) of the Companies Act, 2013 and on the basis of such checks and audit procedures as we considered appropriate and as per information and explanations given to us and on the basis of our examination of the records of the company, we report that: -

- i.
 - (a) (A) The company has maintained proper records showing full particulars including quantitative details and situation of its Property, Plant and Equipment.
 - (B) The company does not have any intangible assets and therefore this clause of the order regarding maintaining its particulars are not applicable.
 - (b) The Property, Plant and Equipment of the company have been physically verified by the management during the year. No material discrepancies have reportedly been noticed on such verification.
 - (c) The company does not hold any immovable properties and therefore this clause of the order regarding title deeds of the immovable property is not applicable.
 - (d) The company has not revalued its Property, Plant and Equipment (including Right of Use of assets) or intangible assets.
 - (e) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- ii.
 - a) As explained to us, inventories were physically verified during the year by the management at reasonable intervals. In our opinion, the coverage and procedure of verification of inventories were appropriate. No discrepancies of 10% or more in the aggregate for each class of inventory were noticed on verification between the physical stocks and book records.



- b) The company is not availing any working capital limit in excess of five crore rupees, in the aggregate, from banks or financial institutions on the basis of security of current assets.
- iii. The company has not made any investments except fixed deposits with bank/clearing agent, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties. Therefore, clauses 3((iii)(a) to 3(iii)(f) of the Order are not applicable.
- iv. The company has not given any loan or made investment or given guarantee or provided security attracting the provisions of section 185 and 186 of the Companies Act, 2013.
- v. The company has not accepted any public deposits. Accordingly, clause 3(v) of the Order is not applicable.
- vi. Maintenance of cost records has not been prescribed by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for any of the products or services of the company. Accordingly, company has made and maintained all accounts and cost records.
- vii. a) The company is generally regular in depositing with appropriate authorities the undisputed statutory dues including Goods and Service Tax, provident fund, employees' state insurance, income-tax, sales tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues applicable to it. Further, there were no arrears of undisputed statutory dues outstanding as at last day of the financial year concerned for a period of more than six month from the date they became payable.
- b) There are no such statutory dues which have not been deposited on account of any dispute except Income Tax Assessments in process with Income Tax Department.
- viii. There were no transactions not recorded in the books of account that have been surrendered or disclosed by the company as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- ix. a) The company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- b) According to the information and explanations given to us, the company has not been declared willful defaulter by any bank or financial institution or other lender.




- c) According to the information and explanations given to us, term loans obtained by the company were applied for the purpose for which they were obtained.
- d) The company has not used funds raised on short term basis for long term purposes.
- e) The company has not taken funds from any entity or person on account of or to meet the obligations of its subsidiary. The company does not have any associates or joint ventures.
- f) The company has not raised loans on the pledge of securities held in the subsidiary. The company does not have associates or joint ventures.
- x. a) The company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.
- b) The company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.
- xi. a) No fraud on or by the company has been noticed or reported during the year.
- b) No report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors during the year in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;
- c) The provisions of sub-section (9) of section 177 of the Act regarding establishment of vigil/whistle-blower mechanism are not applicable to the company.
- xii. The company is not a Nidhi company. Accordingly, clause 3(xii) of the Order is not applicable.
- iii. All the transactions with the related parties are in compliance with the provisions of sections 177 and 188 of Companies Act, 2013 and the details have been properly disclosed in the financial statements as required by the applicable accounting standards.
- v. a) In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per the provisions of the Companies Act, 2013.



- b) The provisions of section 138 of the Act regarding appointment of Internal Auditors are not applicable to the company. Accordingly, clause 3(xiv)(b) of the Order is not applicable.
- xv. The company has not entered into any non-cash transactions with its directors or persons connected with them and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the company.
- xvi. a) The company is not required to be registered under section 45-1A of the Reserve Bank of India Act, 1934 (2 of 1934).
- b) The company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.
- c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- d) The Group does not have any CIC. Accordingly, clause 3(xvi)(d) of the Order is not applicable.
- xvii. The Company has incurred the cash losses in the current and in the immediately preceding financial year as well.
- xviii. There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all



liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

- xx. Provisions of Section 135 of the Companies Act, 2013 are not applicable to the company. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.
- xi. As the report is in respect of standalone financial statements, therefore, clause 3 (xxi) of the Order is not applicable.

For GAGAN JAIN & ASSOCIATES
Chartered Accountants

UDIN- 22529925BDQEXP2868

FCA Gagan Jain
Proprietor
Membership No.529925

Place:- MEERUT
Date:- 23.09.2022



Annexure 'B' to Independent Auditors' Report

Referred to in Paragraph 2 (f) under the heading of "report on other legal and regulatory requirements" of our report of even date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **CHANDAN PHARMACY LIMITED** ("the Company") as of March 31, 2022 in conjunction with our audit of the Financial Statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on internal policies & procedures, accounting records and essential components on the internal control over financial reporting criteria established by the Company as per Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.



Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.


We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Financial Statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the provisions or procedures may deteriorate.



Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on the Company's internal policies & procedures and accounting records and implementation of essential components on the internal controls over financial reporting.

For GAGAN JAIN & ASSOCIATES
Chartered Accountants

UDIN- 22529925BDQEXP2868

FCA Gagan Jain
Proprietor
Membership No.529925

Place:- MEERUT
Date:- 23.09.2022



Chandan Pharmacy Limited
 Corp. off. Add.: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021
 CIN: U52601DL2017PLC322118
Balance Sheet as at 31-Mar-2022

Particulars	Note No.	in ₹ (Thousand)	
		as at 31-Mar-2022	as at 31-Mar-2021
EQUITY AND LIABILITIES			
I. Shareholders' Funds			
(a) Share Capital		499.32	37.62
(b) Reserves and Surplus	4	32.30	15.00
(c) Money Received Against Share Warrants	5	467.02	22.62
2 Share Application money pending allotment			
3 Non-Current Liabilities			
(a) Long-Term Borrowings		-	-
(b) Deferred Tax Liabilities (Net)		-	-
(c) Other Long-Term Liabilities		-	-
(d) Long-Term Provisions		-	-
4 Current Liabilities			
(a) Short-Term Borrowings		1,156.27	839.05
(b) Trade Payables		-	-
(i) Total outstanding dues of micro and small enterprises	6	-	-
(ii) Total outstanding dues of other than micro and small enterprises		83.78	85.13
(c) Other Current Liabilities	7	651.79	657.24
(d) Short-Term Provisions		168.64	70.46
Total		52.06	26.22
		1,655.58	876.67
II. ASSETS			
1 Non-Current Assets			
(a) (i) Property, Plant and Equipment	8	250.12	16.10
(ii) Capital Work-in-Progress		10.89	7.45
(iii) Intangible Assets		-	-
(iv) Intangible Assets under Development		-	-
(b) Non-Current Investments	9	114.75	-
(c) Deferred Tax Assets (Net)		0.00	-
(d) Long-Term Loans and Advances	10	120.49	0.00
(e) Other Non-Current Assets	11	4.00	8.63
2 Current Assets			
(a) Current Investments		1,405.46	860.57
(b) Inventories	12	533.00	342.46
(c) Trade receivables	13	627.67	483.38
(d) Cash and Cash Equivalents	14	28.81	33.58
(e) Short-Term Loans and Advances	15	215.98	1.16
(f) Other Current Assets		-	-
Total		1,655.58	876.67

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1, 2 & 3

The Notes referred to above form an integral part of the Balance Sheet.

As per our report of even date
 For Gagan Jain & Associates
 Chartered Accountants
 Firm Reg No : 020482C

(CA, Gagan Jain)
 Proprietor
 Membership No : 529925
 Address : 122, Dharam Buri, Sadar Bazar, Meerut-250001
 Place Meerut
 Date: 23/09/2022



For and On behalf of the Board



(Dr. Amar Singh)
 Director



(Aamita Singh)
 Director

Chandan Pharmacy Limited
 Corp. off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021
 CIN: U52601DL2017PLC322118
Statement of Profit and Loss for the year ended 31-Mar-2022

Particulars		In ₹ (Thousand)	
	Note No.	1-Apr2021 to 31-Mar2022	1-Apr2020 to 31-Mar2021
I	Revenue from Operations		
II	Other Income	4,446.79	2,874.42
III	TOTAL REVENUE (I + II)	2.27	8.20
IV	EXPENSES	4,449.06	2,882.62
	Cost of Materials Consumed	-	-
	Purchases of Stock-in-Trade	4,183.00	2,744.89
	Changes in Inventories	(190.54)	(105.44)
	Employee Benefit Expenses	190.02	151.30
	Finance Costs	1.08	1.22
	Depreciation and Amortization Expenses	1.16	2.05
	Other Expenses	250.29	49.88
	TOTAL EXPENSES	4,444.92	2,843.70
V	Profit before Exceptional and Extraordinary Items and Tax (III-IV)	4.14	38.93
VI	Exceptional Items	-	-
VII	Profit before Extraordinary Items and Tax	4.14	38.93
VIII	Extraordinary Items	-	-
IX	Profit Before Tax	4.14	38.93
X	Tax Expense		
	Current Tax	1.44	11.33
	Deferred Tax	-	-
XI	Profit/(Loss) for the period from Continuing Operations (IX-X)	2.70	27.60
XII	Profit/(Loss) from Discontinuing Operations	-	-
XIII	Tax Expense of Discontinuing Operations	-	-
XIV	Profit/(Loss) from Discontinuing Operations (after tax) (XII-XIII)	-	-
XV	Profit/(Loss) for the Period (XI+XIV)	2.70	27.60
XVI	Earnings per Equity Share		
	-Basic		
	-Diluted		

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1,2 & 3

The Notes referred to above form an integral part of the Balance Sheet.


As per our report of even date
 For Gagan Jain & Associates
 Chartered Accountants
 Firm Reg. No : 020462C

(CA, Gagan Jain)
 Proprietor

Membership No. : 529928
 Address : 122, Dharam Puri, Sadar Bazar, Meerut-250001
 Place: Meerut
 Date: 23/09/2022



For and on behalf of the Board
 Director
 (Or Amar Singh)
 Director



Director
 (Asmita Singh)
 Director



Chandan Pharmacy Limited
Notes to and forming part of Balance Sheet as at 31-Mar-2022

Particulars	In ₹ (Thousand)			
	as at 31-Mar-2022		as at 31-Mar-2021	
	Number	Amount	Number	Amount
Share Capital				
Authorised 100,00,000 Equity Shares of Rs 10/- each				
(Previous Year 48,00,000 Equity Shares of Rs. 10/- each)	49,00,000	490.00	49,00,000	490.00
Issued 3,22,996 Equity Shares of Rs 10/- each				
(Previous Year 1,50,004 Equity Shares of Rs 10/- each)	3,22,996	32.30	1,50,004	15.00
Subscribed and Fully Paid 3,22,996 Equity Shares of Rs 10/- each				
(Previous Year 1,50,004 Equity Shares of Rs 10/- each)	3,22,996	32.30	1,50,004	15.00
TOTAL	3,22,996	32.30	1,50,004	15.00

Notes:

a) Shares held by each shareholder holding more than 5% shares as on period end.

Name of shareholder	as at 31-Mar-2022		as at 31-Mar-2021	
	% Held	Shares(Nos)	% Held	Shares(Nos)
Amar Singh	18.58	60,000	40.00	60,000
Anant Singh	12.38	40,000	26.67	40,000
Vinay Lamba	6.19	20,001	13.33	20,001
Asmita Singh	-	-	6.67	10,000
Amar/Anita Holdings (India) Private Limited	-	-	6.67	10,001
Chandan Healthcare Limited	53.56	1,72,992	-	-

b) Reconciliation of opening and closing outstanding no. of shares

Particulars	as at 31-Mar-2022		as at 31-Mar-2021	
	Number	Amount	Number	Amount
Equity Shares Subscribed				
Opening Balance	1,50,004	15.00	-	-
Fresh Issue	1,72,992	17.30	1,50,004	15.00
Bonus	-	-	-	-
Buyback	-	-	-	-
Closing Balance	3,22,996	32.30	1,50,004	15.00

5. Reserves and Surplus

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
Surplus		
Opening Balance	22.62	(4.72)
(+/-) Net profit/(Net loss) for the Current Year	2.70	27.60
(+/-) MAT Credit Adjustment	-	(0.43)
(+/-) Dividend	(15.00)	-
(+/-) Deferred Tax Assets	-	0.17
(+/-) Share Premium	456.70	-
Closing balance	467.02	22.62
Total	467.02	22.62



4A. SHARES HELD BY PROMOTORS

Current Reporting Period

Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Amar Singh	60,000	18.58	- 21.42
2	Anant Singh	40,000	12.38	- 14.28
3	Asmita Singh	10,000	3.10	- 3.57
4	Vijay Singh	5,001	1.55	- 1.79
5	Vinay Lamba	20,001	6.19	- 7.14
6	Virendra Singh	5,001	1.55	- 1.79
7	AmarAnita Holdings (India) P Ltd	10,001	3.10	- 3.57

Previous reporting Period

Sr No.	Promotor's Name	No of shares	% of total shares	% Change during the year
1	Amar Singh	60,000	40.00	0.00
2	Anant Singh	40,000	26.67	0.00
3	Asmita Singh	10,000	6.67	0.00
4	Vijay Singh	5,001	3.33	0.00
5	Vinay Lamba	20,001	13.33	0.00
6	Virendra Singh	5,001	3.33	0.00
7	AmarAnita Holdings (India) P Ltd	10,001	6.67	0.00



Trade Payables

Figures For the Current Reporting Period

Particulars	Outstanding for following periods from due date of payment				In ₹ (Thousand)
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	83.78	-	-	-	83.78
Others	851.79	-	-	-	851.79
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total	-	-	-	-	935.57

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
MSME	85.13	-	-	-	85.13
Others	657.24	-	-	-	657.24
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total	-	-	-	-	742.37



Chandan Pharmacy Limited
Notes to and forming part of Balance Sheet as at 31-Mar-2022

Other Current Liabilities	Particulars	In ₹ (Thousand)	
		as at 31-Mar-2022	as at 31-Mar-2021
	Current Maturities of Finance Lease Obligations	-	-
	Interest Accrued but not due on Borrowings	-	-
	Interest Accrued and due on Borrowings	-	-
	Income Received in Advance	-	-
	Unpaid Dividends	-	-
	Application money received for allotment of securities and due for refund and interest accrued thereon	-	-
	Unpaid matured Deposits and Interest accrued thereon	-	-
	Unpaid matured Debentures and Interest accrued thereon	-	-
	Other Payables :		
	- Creditors for Expenses	134.54	61.93
	- Creditors for Rent	0.18	-
	- Creditors for Fixed Assets	0.21	-
	- Cheque Issued But Not Cleared	20.00	3.23
	- Payable to Professionals	0.27	-
	- Other Payable	13.45	5.31
	Total	168.64	70.46

10. Short Term Provision

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Provision for Employee Benefits	37.66	13.89
(h) Others (specify nature)	-	-
- Audit Fees Payable	0.87	0.62
- Income Tax Payable	9.65	9.65
- TDS Payable	3.88	2.06
Total	52.06	26.22



Non-Current Investments		
Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Investment property	-	-
(b) Investments in Equity Instruments	114.75	-
(c) Investments in preference shares	-	-
(d) Investments in Government or trust securities	-	-
(e) Investments in debentures or bonds	-	-
(f) Investments in Mutual Funds	-	-
(g) Investments in partnership firms	-	-
(h) Other non-current investments (specify nature)	-	-
Total	114.75	-

13. Long Term Loans & Advances

In ₹ (Thousand)

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Capital Advances	-	-
(c) Loans and Advances to Related Parties	117.71	8.63
(h) Other loans and advances (specify nature)	-	-
Secured, considered good;		
- Loan & Advance to Employee	2.78	-
Total	120.49	8.63

14. Other Non-Current Assets

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Security Deposits	4.00	-
(b) Other (specify nature)	-	-
Secured, considered good;		
Total	4.00	-

15. Inventories

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Raw Materials	-	-
(b) Work-in-progress	-	-
(c) Finished goods	-	-
(d) Stock-in-trade	533.00	342.48
(e) Stores and spares	-	-
(f) Loose tools	-	-
(g) Others (specify nature)	-	-
Total	533.00	342.48



Cash and Cash Equivalents		
Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Balances with banks		
Earmarked Balances		
in Current Account		
Margin Money	-	-
Security Against Borrowings	1.26	32.44
Guarantees	-	-
Other Commitments (Security/earnest money)	-	-
Bank deposits with more than 12 months maturity	-	-
(b) Cheques, drafts on hand	-	-
(c) Cash on hand	-	-
(d) Others	-	-
Total	27.55	1.14
	28.81	33.58

18 . Short Term Loans and Advances

Particulars	as at 31-Mar-2022	as at 31-Mar-2021
(a) Loans and Advances to Related Parties	-	-
(b) Other Loans and Advances		
Unsecured, considered good		
- Goods & Service Tax	9.05	0.51
- Advance for Expenses	3.05	0.37
- Advance to Supplier	3.45	
- Advance for Fixed Assets	1.38	
- Advance Tax	0.11	
- Sundry Debtors	198.91	0.28
- Other Misc Advance	-	-
Total	215.98	1.16



16 TRADE RECEIVABLES
 Figures For the Current Reporting Period

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	627.67	-	-	-	-	627.67
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total	627.67					627.67

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	483.38	-	-	-	-	483.38
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total	483.38					483.38



CPL

SCHEDULE - B

Schedule Of Fixed Assets & Depreciation as per Companies Act 1956
For the Year ended 31st March 2022

In ₹ (Thousands)

Sno	ASSETS	Life	GROSS BLOCK				AS ON 14/2/2020	DURING THE YEAR	ADJ	TOTAL	WDV AS ON 31-03-2022	WDV AS ON 31-03-2021
			AS ON 14/2/21	ADDITIONS DURING THE YEAR	ADJ	AS ON 31/03/21						
1	Computers	3Yr	435	-	-	435	0.31	-	3.78	0.58	0.89	
2	Office Equipments	5Yr	195	0.40	-	2.34	0.40	-	1.58	0.76	0.76	
3	Furniture & Fixtures	10Yr	3.47	4.19	-	7.66	0.39	-	1.36	6.31	2.51	
4	Office Interior and Renovation	60Yr	3.59	-	-	3.59	0.06	-	0.34	3.25	3.30	
	TOTAL		13.36	4.59		17.95	1.16		7.06	10.89	7.46	



Chandan Pharmacy Limited

Notes to and forming part of Statement of Profit and Loss for the year ended 31-Mar-2022

19. Revenue From Operations

Particulars	In ₹ (Thousand)	
	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Sales of Product		
Sales of Services	4,446.79	2,874.42
Other Operating Revenues	-	-
Total	4,446.79	2,874.42

20. Other Income

Particulars	In ₹ (Thousand)	
	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Interest Income	-	-
Dividend Income	-	-
Net gain/loss on sale of investments	-	-
Other Non-Operating Income	2.27	8.20
Total	2.27	8.20

21. Purchases of Stock in Trade

Particulars	In ₹ (Thousand)	
	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Purchases of medicine	4,183.00	2,744.69
Total	4,183.00	2,744.69

22. Change in Inventories

Particulars	In ₹ (Thousand)	
	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Opening Balance	342.46	237.01
Less Closing Balance	533.00	342.46
Total	(190.54)	(105.44)



Employee Benefit Expenses

Particulars	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Salary & Wages	182.02	119.55
Contribution to PF & Other Funds	8.55	10.69
Staff Welfare Expenses (Bonus etc.)	9.35	21.06
Total	199.92	151.30

24. Finance Costs

In ₹ (Thousand)

Particulars	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Interest		
Dividend on Redeemable Preference Shares		
Exchange differences regarded as an adjustment to borrowing costs		
Other borrowing costs (specify nature)		
- Bank Charges	1.08	1.22
Total	1.08	1.22

25. Depreciation and Amortization Expenses

Particulars	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Depreciation	1.16	2.05
Total	1.16	2.05

26. Other Expenses

In ₹ (Rupees)

Particulars	1-Apr-2021 to 31-Mar-2022	1-Apr-2020 to 31-Mar-2021
Payment to Auditors		
As Auditor	0.25	0.56
Consumption of stores and spare parts	4.94	1.29
Power & Fuel	0.10	0.10
Rent	37.06	10.91
Repairs to machinery	0.49	0.08
Repairs to Building	2.08	1.95
Insurance	0.37	-
Miscellaneous expenses		
- Professional Fees	4.24	21.45
- Travelling & Conveyance Exp	182.84	0.11
- Commission Exp	14.26	6.03
- ROC & Compliance Exp	0.06	0.03
- Other Mic Exp	3.59	7.37
Total	250.29	49.68



CHANDAN PHARMACY LIMITED

Corp. off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U52601DL2017PLC322118

www.chandan.co.in

Significant Accounting Policies and Notes forming part of the Financial Statements

1. COMPANY OVERVIEW

The Company is engaged in the business of trading of medicine and providing medical diagnostic services to individuals and corporate.

2. SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Preparation of Financial Statements

The Financial Statements are prepared under historical cost convention and on the accrual & going concern basis, in accordance with the generally accepted accounting principles (GAAP) in India, GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified).

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in Revised Schedule VI to the Companies Act, 1956. Based on the nature of the services and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as twelve months for the purpose of current or non-current classification of assets and liabilities.

The Schedule III of Companies Act 2013 is used for the preparation of financial statements. This has a significant impact on the disclosure and presentation in financial statements. Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classification/disclosure. The balances of Personal Account are subject to confirmation & reconciliation. In the opinion of the management, the current assets, loans & advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the Balance Sheet.

b) Use of Estimates

The preparation and presentation of Financial Statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities and disclosure of contingent liabilities on the date of the Financial Statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates is recognised in the period in which the results are known/ materialized.

Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in Estimates are reflected in the financial statements in the period in which changes are made and if material their effects are disclosed in the notes to the financial statements.

c) Fixed Assets

(i) Fixed Assets are stated at cost less accumulated depreciation, amortisation and impairment loss, if any.



c) Expenses incurred relating to project, prior to commencement of commercial operation, are considered as project development expenditure and shown under Capital Work in Progress.

d) Depreciation/ Amortisation

Depreciation on tangible assets is provided on the Straight line Method as per useful life specified in schedule II of the Companies Act, 2013. Depreciation for assets purchased / sold during a period is proportionately charged. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, commencing from the date the asset is available to the Company for its use. Depreciation and amortization methods, useful lives and residual values are reviewed periodically, including at each financial year end

e) Impairment of Assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use.

f) Investments

Current Investments are carried at lower of cost and market value computed investment wise. Long Term Investments are stated at cost or fair value. Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management. Investments in subsidiaries and associates are held for sale in future.

g) Inventories of Stores/Spares and consumables

Inventories of stores and spares are accounted for at cost or net realizable value, whichever is less. Stocks of consumable items has been charged to profit & Loss account on consumption basis.

h) Revenue Recognition

Revenue is recognized to the extent that it can be reliably measured and is probable that the economic benefit will flow to the company. Revenue from sale of goods is recognized when the significant risks and rewards of ownership of the goods are transferred to the customer.

Sales are accounted net of amount recovered towards excise duty, sales tax and sales returns.

Sales returns are accounted on actual receipt of return goods / settlement of claims.

Services are accounted for pro-rata over the period of contract.

Interest income is recognized on pro-rate basis.

Dividend income is recognized when right to receive the dividend is established.

i) Taxes on Income and Deferred Tax


Provision for Income Tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of Current Tax and Deferred Tax at the applicable enacted or substantively enacted rates. Current Tax represents the amount of Income Tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred Tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The Deferred Tax Asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, Deferred Tax Assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

j) Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognised when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that



may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognised nor disclosed in the Financial Statements.

k) Earning per Share

In determining Earning per Share, the Company considers the net profit after tax and includes the post tax effect of any extraordinary / exceptional item. The number of shares used in computing Basic Earning per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing Diluted Earning per Share comprises the weighted average shares considered for deriving Basic Earnings per Share and also the weighted average number of shares that could have been issued on the conversion of all dilutive potential equity shares unless the results would be anti-dilutive. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date.

l) Employee Benefits

a. Short term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short term employee benefits.

b. Long Term Employees benefits

The provision for the Gratuity amount has been estimated and provided for. The present value of obligation under such defined benefit plan is determined based on actuarial valuation. The gratuity obligation recognized in Balance Sheet represent the actual deficit in the Company's defined benefit plans.

m) Lease

Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the Statement of Profit and Loss on a straight line basis over the lease term.

Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor.

Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

n) The Company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.



[Signature]
Dr. Amar Singh
(Director)



[Signature]
Asmita Singh
(Director)

Place: Lucknow
Date: 8/Sep/2022





BOARD REPORT TO THE MEMBERS

To the Share Holders for the year ended 31st March, 2022

To,
The Share Holders,

Your Directors present the company's 5th Annual Report on the business and operations of the Company along with the Audited Balance Sheet and Profit & loss Account for the year ended 31st March 2022.

1. Financial summary and working results:-

(In Thousand)

	For the year 2021-22	For the year 2020-21
Gross Income	4446.79	2874.42
(Loss)/Profit before Tax	4.14	38.93
Tax Expense	(1.44)	(11.33)
(Loss)/Profit After Tax	2.70	27.60
Balance b/f from previous year	22.62	(4.72)
Less: Appropriation	0	0
Balance c/f to Balance Sheet	467.02	22.62

2. Reserves & Surplus

Out of the total profit of Rs. 467.02 for the Financial Year, entire amount is proposed to be transferred to the General Reserve.

3. Dividend

During the financial year ended 31st March, 2022 your Directors have announced & paid Interim Dividend of Rs. 1.00 per share.

There are no recommendation to pay final dividend, accordingly Interim Dividend paid during the year shall be the Final Dividend.

4. Brief description of the company's working during the year/state of company's affair

Company is dealing in trading of pharmaceuticals items. Company is dedicated to provide genuine medicines to society at reasonable rate.



5. Events subsequent to the date of Financial Statements

There is n material changes and commitments affecting the financial position of the company occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

6. Significant & Material orders passed by the regulators

During the year no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

7. Details of Subsidiaries and Associates

Details of the Companies which have become / ceased to be its Subsidiary/ JV/ Associate Company

S.No	Name	Status Subsidiary z/JV/ Associate company	Date of becoming Subsidiary/ JV/ Associate Company	Date of ceasing as Subsidiary/ JV/ Associate Company
1	Chandan Healthcare Limited	Holding Company	26/02/2022	--

8. Deposits

There are no Deposits accepted during the year and no balance outstanding at the year end.

9. Changes in share capital

There are no changes in share capital of the company.

10. Statutory Auditors

The statutory auditor, Gagan Jain & Associates were appointed as the Statutory Auditors of the Company for a period of Five years to hold their office up to the Financial Year ending 2027 subject to ratification at Annual General Meeting in terms of Section 139 of the Companies Act 2013.

11. Auditors' Report

The Auditors' Report does not contain any qualification. Notes to Accounts and Auditors' remarks in their report are self-explanatory and do not call for any future comments.

12. Environment, safety and energy conservation

The relevant data pertaining to conservation of energy, technology absorption and other details are mentioned below:

Conservation of Energy:

The contribution by the company towards conservation of energy is limited to in house, office administration and operational process. Company has taken precautions and has made all efforts for conservation of energy. Company's operation does not consume significant amount of energy.

Technology Absorption: - Company constantly makes efforts to use latest Technologies.

Research and Development: - NA

Benefits derived as a result of the above R&D efforts :- NA

13. Foreign exchange earnings and outgo

During the year the total foreign exchange earned was NIL and utilized also was NIL.

14. Disclosure under the sexual harassment of women at workplace(Prevention, Prohibition and Rederessal) Act, 2013

The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy. The Company did not receive any complain during the year 2021-22.

15. Number and Date of meetings of the Board of Directors

Eight Board meeting were held during the year, details of which are as follows:-

S.No.	Date of Meeting
1	25/06/2021
2	05/08/2021
3	10/10/2021
4	05/11/2021
5	20/12/2021
6	30/12/2021
7	03/02/2022
8	26/02/2022

16. The following table gives the attendance record of the directors at the above said Board Meetings and at the last Annual General Meeting

Director	No. of Board Meetings Held	No. of Board Meetings Attended	Last AGM Attended
Dr.Amar Singh	9	9	Yes
Asmita Singh	9	9	Yes
Anant Singh	9	9	Yes
Rajive Kumar	9	8	Yes
Vinay Lamba	9	0	No
Aasti Singh	9	0	No

17. Particulars of loans, guarantees or investments under section 186

S.N.	Particulars of Loans, Guarantee & Investments	Nature	Amount
1.	Shares in Chandan Institute Of Medical Sciences Limited	Investment	42,50,000

18. Particulars of contracts or arrangements with related parties

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013, in the prescribed Form AOC-2, is appended as Annexure 1 to the Board's report.

19. Corporate Governance

All the directors do not receive any benefit from the company except salary as follows:-

S.No.	NAME OF THE DIRECTOR	TOTAL SALARY
1	Dr.Amar Singh	NIL
2	Asmita Singh	NIL
3	Anant Singh	34,32,000
4	Rajive Kumar	NIL
5	Vinay Lamba	NIL
6	Aasti Singh	NIL

As the liability for Gratuity is provided on an actuarial basis for the Company as a whole, the amount pertaining to Directors is not ascertainable and, therefore, not included in the above.

20. Risk Management Policy

Risk Management Policy at **Chandan Pharmacy Limited** seeks to identify the following risks

- Corporate Strategy Risk
- Management Risk
- Operational Risks

and provides guidelines to define, measure, report, control and mitigate the identified risks.

The objective of Risk Management at **Chandan Pharmacy Limited** is to create and protect shareholder value by minimizing threats or losses, and identifying and maximizing opportunities and includes:-

1. Providing a framework that enables future activities to take place in a consistent and controlled manner
2. Improving decision making, planning and prioritization by comprehensive and structured understanding of business activities, volatility and opportunities/ threats
3. Contributing towards more efficient use/ allocation of the resources within the organization
4. Protecting and enhancing assets and company image
5. Developing and supporting people and knowledge base of the organization.
6. Optimizing operational efficiency

The Board's role is to ensure framing, implementing and monitoring risk management plan, and that the systems in place for risk management as part of internal controls with duty being cast upon Directors to bring unbiased opinion to the Board's attention.

Every employee who identifies any potential risk shall report to his senior or departmental head further Risk Identification is obligatory on all functional directors and departmental heads who with the inputs from their team members are required to report the material risks to the Chairman and Managing Director along with their views and recommendations for risk minimization.

The Board shall authorize a executive team to implement the approved strategy and team shall submit its report on timely basis to ascertain the risk minimization or elimination.

21. Transfer of amounts to investor education and protection Fund

Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore there were no funds which were required to be transferred to Investor Education and Protection Fund(IEPF).

22. Directors' Responsibility Statement

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that—

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the

state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) the directors had prepared the annual accounts on a going concern basis; and

(e) the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

23. Acknowledgement

The Directors commend the continuing commitment and dedication of employees at all levels. The Directors would also like to thank all other stakeholders, Bankers & other business associates, who have provided sustained support and encouragement. The Directors look forward to their continued support in the years to come.

For & On Behalf of Board of Directors
Chandan Pharmacy Limited



(Dr. Amar Singh)
Director
DIN:01096328

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

Date: - 02/09/2022
Place: -Lucknow



(Mrs. Asmita Singh)
Director
DIN:01098055

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

Annexure I

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

1. Details of contracts or arrangements or transactions not at Arm's length basis: NA

Sr. No.	Particulars	Details
1	Name (s) of the related party & nature of relationship	
2	Nature of contracts/arrangements/transaction	
3	Duration of the contracts/arrangements/transaction	
4	Salient terms of the contracts or arrangements or transaction including the value, if any	
5	Justification for entering into such contracts or arrangements or transactions'	
6	Date of approval by the Board	
7	Amount paid as advances, if any	
8	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of material contracts or arrangement or transactions at arm's length basis:

Sr. No.	Particulars	A	B	
1	Name (s) of the related party & nature of relationship	Chandan Hospital Limited (Company in which a Director is a Director and holds along with his/her relatives, more than 2% of its paid-up share capital)	Chandan Diagnostic Limited (Company in which a Director is a Director and holds along with his/her relatives, more than 2% of its paid-up share capital)	Chandan Healthcare Limited (Company in which a Director is a Director and holds along with his/her relatives, more than 2% of its paid-up share capital)
2	Nature of contracts/arrangements/transaction	Debit Balance o/s	Debit Balance o/s	Debit Balance o/s
3	Duration of the contracts/arrangements/transaction	1 Year	1 Year	1 Year
4	Salient terms of the contracts or arrangements or transaction including the value, if any	6,27,50,987/-	8,03,281/-	91,84,908/-
5	Amount paid as advances, if any	NIL	NIL	NIL

For & On Behalf of Board of Directors
Chandan Pharmacy Limited



Director
Lucknow

(Dr. Amar Singh)
Director
DIN:01096328

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

Date: - 02/09/2022

Place: -Lucknow



Director
Lucknow

(Mrs. Asmita Singh)
Director
DIN:01098055

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015



CHANDAN PHARMACY LIMITED

Reg Off. Add.: A-15, VIVEK VIHAR, PHASE-1, DELHI-110095

CIN: U52601DL2017PLC322118

www.chandan.co.in



NOTICE TO MEMBERS

Notice is hereby given that the 5th Annual General Meeting of the Share Holders of the company will be held at corporate office of the company at Biotech Park, Sector-G, Jankipuram, Lucknow on 30/09/2022 at 12:00 to transact the following businesses:

ORDINARY BUSINESS BY ORDINARY RESOLUTION

1. To Approve and adopt the audited Balance Sheet as at 31st March 2022 and the Statement of Profit & Loss Account for the Year ended on that date along with Auditors Report and Directors Report thereon. To consider and if thought fit to pass with or without modification(s) the following resolution as an Ordinary Resolution :

"RESOLVED THAT the Audited Balance Sheet and the Statement of Profit & Loss Account, Directors' Report and Auditors' Report for the year ended on 31st March, 2021 together with the schedules mentioned therein be and are hereby approved and adopted."

2. To appoint a director in place of Mrs. Asmita Singh, who retires by rotation and being eligible offers herself for re-appointment.

For & On Behalf of Board of Directors
Chandan Pharmacy Limited

Date: - 02/09/2022

Place: -Lucknow

(Dr. Amar Singh)
Director
DIN:01096328

(Mrs. Asmita Singh)
Director
DIN:01098055

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015



NOTES:

1. A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote, instead of himself/herself, and such proxy need not be a member of the company. proxy in order to be effective must be filed with the company at its registered office not later than forty eight hours before the meeting.
2. Corporate members intending to send their authorised representatives to attend the Meeting, are requested to send a certified copy of the Board Resolution authorising their representative to attend and vote on their behalf, at the Meeting.
3. The members are requested to intimate the change of address immediately to the company.
4. All documents referred to in accompanying Notice shall be open for inspection at the Registered Office of the Company during the office hours on all working days between 10 am to 6 pm up to the date of conclusion of AGM.
5. Explanatory Statement as required under Section 102(1) of the Companies Act, 2013, relating to the Special Business to be transacted at the Meeting is annexed hereto.